Breaking News Instant updates and real-time market news.

CDE

Coeur Mining

$8.39

-0.03 (-0.36%)

, WCC

Wesco

$53.95

-1.85 (-3.32%)

06:55
06/22/17
06/22
06:55
06/22/17
06:55

Goldman to hold a conference

2nd Annual Leveraged Finance Conference is being held in Rancho Palos Verdes, CA on June 19-21.

CDE

Coeur Mining

$8.39

-0.03 (-0.36%)

WCC

Wesco

$53.95

-1.85 (-3.32%)

SABR

Sabre

$22.52

-0.26 (-1.14%)

UNIT

Uniti Group

$26.11

-0.82 (-3.04%)

VRX

Valeant

$13.68

0.53 (4.03%)

AMAG

Amag Pharmaceuticals

$17.75

0.9 (5.34%)

MSCC

Microsemi

$48.55

0.52 (1.08%)

CRC

California Resources

$8.01

-0.69 (-7.93%)

LPNT

LifePoint

$64.85

0.25 (0.39%)

UIS

Unisys

$12.43

0.08 (0.65%)

BLL

Ball Corp.

$41.78

-0.01 (-0.02%)

TTMI

TTM Technologies

$18.03

0.16 (0.90%)

AMKR

Amkor Technology

$10.68

0.01 (0.09%)

  • 22

    Jun

  • 26

    Jun

  • 03

    Aug

  • 24

    Aug

  • 29

    Aug

CDE Coeur Mining
$8.39

-0.03 (-0.36%)

10/10/16
ROTH
10/10/16
NO CHANGE
Target $16
ROTH
Buy
Coeur Mining price target lowered to $16 from $17.50 at Roth Capital
Roth Capital analyst Joe Reagor noted that Coeur Mining's Q3 production came in below his estimates, but the company still raised full year guidance, as anticipated. Reagor cut his price target on Coeur to $16 from $17.50 to reflect the recent decline in precious metal prices, but maintains a Buy rating on the stock.
10/03/16
DBAB
10/03/16
UPGRADE
DBAB
Hold
Coeur Mining upgraded to Hold from Sell at Deutsche Bank
08/30/16
CIBC
08/30/16
UPGRADE
CIBC
Sector Performer
Coeur Mining upgraded to Sector Performer from Underperformer at CIBC
10/25/16
ADAM
10/25/16
INITIATION
Target $13
ADAM
Buy
Coeur Mining initiated with a Buy at Canaccord
Canaccord analyst Peter Bure initiated Couer Mining with a Buy rating and $13 price target as he believes silver prices will continue to appreciate over the next 12-18 months as zinc and lead mine closures impact supply.
WCC Wesco
$53.95

-1.85 (-3.32%)

04/28/17
FBCO
04/28/17
NO CHANGE
Target $76
FBCO
Outperform
WESCO price target lowered to $76 from $83 at Credit Suisse
Credit Suisse analyst Andrew Buscaglia lowered his price target for WESCO to $76 from $83 saying that the company's results mirrored distributor peers in which end market growth finally transpired in Q1, yet margins came in at the low end of guidance. The analyst reiterates an Outperform rating on the shares.
12/05/16
WBLR
12/05/16
UPGRADE
WBLR
Outperform
WESCO upgraded to Outperform from Market Perform at William Blair
William Blair analyst Ryan Merkel upgraded WESCO to Outperform saying now is the time to own short-cycle industrials. Longbow this morning also upgraded the shares.
04/19/17
RAJA
04/19/17
UPGRADE
Target $70
RAJA
Outperform
WESCO upgraded to Outperform from Market Perform at Raymond James
Raymond James analyst Sam Darkatsh upgraded WESCO to Outperform with a $70 price target saying business is improving and pricing should be supported by commodity inflation and improved industry activity.
05/02/17
MSCO
05/02/17
UPGRADE
Target $74
MSCO
Overweight
WESCO upgraded to Overweight from Equal Weight at Morgan Stanley
Morgan Stanley analyst Nigel Coe upgraded WESCO to Overweight with a $74 price target telling investors it has strong cyclical upside from a continued recovery in US IP and capex, views margin concerns as overblown, and expects topline growth to continue to accelerate.
SABR Sabre
$22.52

-0.26 (-1.14%)

02/14/17
BOFA
02/14/17
DOWNGRADE
BOFA
Neutral
Sabre downgraded to Neutral from Buy at BofA/Merrill
02/20/17
BOFA
02/20/17
DOWNGRADE
BOFA
Neutral
Sabre downgraded to Neutral from Buy at BofA/Merrill
04/07/17
COWN
04/07/17
NO CHANGE
COWN
Cowen travel agent survey positive for Sabre, Travelport and Expedia
Cowen conducted a travel agent survey to gauge trends on sentiment, demand for airline products, dynamics in the Global Distribution System marketplace, and participation in online travel affiliate programs. The agents skewed bullish overall and the survey was positive for Sabre (SABR), Travelport (TVPT), and Expedia (EXPE), the firm reported. The survey showed meaningful demand for economy products, controlled GDS incentive payment growth, and a majority of respondents said selling ancillary airline services is not financially worthwhile for them, Cowen's analysts noted.
04/06/17
MSCO
04/06/17
DOWNGRADE
Target $24
MSCO
Equal Weight
Sabre downgraded to Equal Weight from Overweight at Morgan Stanley
Morgan Stanley analyst Brian Essex downgraded Sabre to Equal Weight and trimmed his price target to $24 from $26 due to investment spending that will pressure margin expansion and cash flow growth through mid 2018. Essex said Sabre is under-invested in its infrastructure and is making necessary investments to improve responsiveness, reliability and security of its platform going forward but lacks catalysts ahead that indicate better growth and leverage from investments.
UNIT Uniti Group
$26.11

-0.82 (-3.04%)

04/10/17
RHCO
04/10/17
NO CHANGE
RHCO
SunTrust views AT&T deal as highlighting 5G momentum
SunTrust analyst Greg Miller believes AT&T's (T) acquisition of Straight Path (STRP) highlights the "strong momentum" on early 5G network development plans, including fixed wireless. He believes the news is positive for infrastructure companies including Crown Castle (CCI), Zayo Group (ZAYO), Uniti Group (UNIT) and ultimately American Tower (AMT) and SBA Communications (SBAC) in later-stage 5G deployments.
04/11/17
RHCO
04/11/17
NO CHANGE
RHCO
Uniti Group acquisition positive, says SunTrust
After Uniti Group (UNIT) bought Southern Light, SunTrust analyst Greg Miller says that the deal enhances the value of the company's fiber assets and will diversify its revenue. The analyst admits that the company paid a high price, but he thinks it is worthwhile, given the value of the assets it acquired. He keeps a $30 price target and a Buy rating on the shares.
05/22/17
DBAB
05/22/17
INITIATION
Target $28
DBAB
Buy
Uniti Group initiated with a Buy at Deutsche Bank
Deutsche Bank analyst Matthew Niknam started Uniti Group with a Buy rating and $28 price target.
06/19/17
RBCM
06/19/17
INITIATION
RBCM
Outperform
Uniti Group initiated with an Outperform at RBC Capital
RBC Capital analyst Jonathan Atkin started coverage of Uniti with a $32 price target and an Outperform rating. The analyst says that the company has "favorable organic and inorganic growth opportunities (compared with) its peers," partly due to its focus on smaller markets, its "broader customer base," and "strong valuation metrics."
VRX Valeant
$13.68

0.53 (4.03%)

06/16/17
CANT
06/16/17
INITIATION
Target $18
CANT
Overweight
Valeant initiated with an Overweight at Cantor
Cantor Fitzgerald analyst Louise Chen started Valeant Pharmaceuticals with an Overweight rating and $18 price target. The analyst believes Valeant can reduce its debt to manageable levels over the medium term and thinks new management can post earnings upside in 2019 and beyond. The analyst also thinks the negative media attention placed on the company has reduced significantly from a year ago.
06/19/17
WELS
06/19/17
NO CHANGE
WELS
Underperform
Wells says Paulson joining Valeant board likely a 'signal of dissatisfaction'
Wells Fargo analyst David Maris said that while some shareholders might see John Paulson joining Valeant's board as a vote of confidence, he "cannot help but think" this is a "signal of dissatisfaction of some sort." Maris, who maintains his long-held Underperform rating on Valeant, added that he does not know what new domain experience Paulson will bring to the board that was not already present.
06/14/17
RODM
06/14/17
NO CHANGE
Target $6
RODM
Buy
EyeGate price target lowered to $6 from $10 at Rodman & Renshaw
Rodman & Renshaw analyst Raghuram Selvaraju lowered his price target for EyeGate Pharmaceuticals (EYEG( to $6 after the company granted a subsidiary of Valeant Pharmaceuticals (VRX) exclusive commercial and manufacturing rights to the EyeGate II Delivery System and EGP-437 combination product for treatment of post-operative pain and inflammation in ocular surgery patients. The analyst views the development, along with the top-line data from the first-in-human pilot trial of ocular bandage gel in patients with large corneal epithelial defects, as positive developments and raised his valuation of the company to $112M from $80M. His lowered target reflects higher shares outstanding. Selvaraju reiterates an Outperform rating on EyeGate.
06/09/17
WELS
06/09/17
NO CHANGE
WELS
Outperform
Wells says Valeant's focus on EBITDA ignores rising borrowing costs
After Valeant Pharmaceuticals issued a regulatory filing with financial data for its just sold iNova Pharmaceuticals unit, Wells Fargo analyst David Maris says that while the company is executing deals and reducing absolute debt, "leverage seems to be relatively unchanged." Valeant's focus on EBITDA versus earnings is to have investors "ignore the impact of increased borrowing costs and any impact from potential dilutive equity based financing," Maris tells investors in a research note. Valeant has indicated an equity raise is not off the table, the analyst adds. He has an Underperform rating on the stock with a $9 price target. Valeant in afternoon trading is down 26c to $13.00.
AMAG Amag Pharmaceuticals
$17.75

0.9 (5.34%)

03/15/17
RAJA
03/15/17
NO CHANGE
RAJA
Raymond James says new study highlights risks for AMAG
Raymond James analyst Christopher Raymond says a new study in the American Journal of Obstetrics and Gynecology questions the therapeutic utility of hydroxyprogesterone caproate for preterm birth also highlights a potential safety signal. Hydroxyprogesterone caproate is the active ingredient in AMAG Pharmaceuticals' Makena. The analyst has an Underpeform rating on the shares.
02/03/17
COWN
02/03/17
DOWNGRADE
Target $25
COWN
Market Perform
AMAG Pharmaceuticals downgraded to Market Perform from Outperform at Cowen
Cowen analyst Ken Cacciatore downgraded AMAG Pharmaceuticals to Market Perform from Outperform on the belief that the franchise extension strategy for Makena will unfortunately fail. The analyst also questions the business decisions made after acquiring Makena, such as buying CBR, which could prove to be value destroying. Cacciatore lowered his price target to $25 from $35 on AMAG Pharmaceuticals shares.
01/31/17
JPMS
01/31/17
NO CHANGE
Target $24
JPMS
Neutral
AMAG Pharmaceuticals price target lowered to $24 from $33 at JPMorgan
JPMorgan analyst Jessica Fye lowered her price target for AMAG Pharmaceuticals to $24 following updates at her firm's healthcare conference, including the shift in Makena strategy, Rekynda in-licensing and 2017 guidance. The analyst keeps a Neutral rating on the shares.
01/10/17
NEED
01/10/17
DOWNGRADE
NEED
Hold
AMAG Pharmaceuticals downgraded to Hold from Buy at Needham
MSCC Microsemi
$48.55

0.52 (1.08%)

06/14/17
RBCM
06/14/17
DOWNGRADE
RBCM
Outperform
Microsemi downgraded to Outperform from Top Pick at RBC Capital
06/14/17
RBCM
06/14/17
DOWNGRADE
RBCM
Outperform
Microsemi downgraded on stock outlook at RBC Capital
As noted earlier, RBC Capital downgraded Microsemi to Outperform from Top Pick. Analyst Mitch Steves expects the stock to appreciate at a "steady" rate going forward if the company executes well. As a result, he believes that an Outperform rating is more appropriate for the shares than a Top Pick rating. Target to $58 from $64.
06/15/17
RAJA
06/15/17
INITIATION
RAJA
Market Perform
Microsemi initiated with a Market Perform at Raymond James
Raymond James analyst Chris Caso resumed coverage on Microsemi with a Market Perform saying cost reduction opportunities are complete and the industry is in the later stages of the upturn.
05/22/17
RBCM
05/22/17
NO CHANGE
RBCM
Microsemi can benefit from Saudi defense deal, says RBC Capital
RBC Capital analyst Mitch Steves says that the approximately $110B defense deal between the U.S. and Saudi arabia has "improved the long-term trajectory" of Microsemi's aerospace and defense business. The analyst thinks the deal could help enable the company's EPS to exceed $4 over the longer term. He keeps a Top Pick rating on the shares.
CRC California Resources
$8.01

-0.69 (-7.93%)

11/22/16
MSCO
11/22/16
UPGRADE
MSCO
Equal Weight
California Resources upgraded to Equal Weight at Morgan Stanley
11/22/16
11/22/16
UPGRADE
Target $21

Equal Weight
California Resources upgraded to Equal Weight at Morgan Stanley
As previously reported, Morgan Stanley upgraded California Resources to Equal Weight from Underweight with a $21 price target. Analyst Evan Calio said California Resources has the highest leverage to crude ahead of the OPEC meeting on November 30, which drives a positive risk/reward into the end of the year.
LPNT LifePoint
$64.85

0.25 (0.39%)

06/06/17
MSCO
06/06/17
INITIATION
Target $65
MSCO
Equal Weight
LifePoint initiated with an Equal Weight at Morgan Stanley
Morgan Stanley analyst Zack Sopcak initiated LifePoint with an Equal Weight rating and $65 price target, citing volume and price pressures on the hospital industry expected over the next several years.
05/31/17
PIPR
05/31/17
NO CHANGE
PIPR
Piper raises 'early caution flag' for Q2 hospital earnings
Following her firm's May outpatient survey, Piper Jaffray analyst Sarah James is putting up an "early caution flag" for Q2 hospital earnings. The May outpatient survey indicates April was the peak, declining in May, with indications that June could be below April as well, James tells investors in a research note. After four months of increases, the outpatient survey declined 50 basis points from the April peak to 2.5% year-over-year same-hospital admissions in May, the analyst adds. She views the decline as concerning amid "tenuous" investor sentiment and "optimistic" Q2 expectations. Hospitals that Piper covers include Community Health (CYH), HCA Holdings (HCA), LifePoint (LPNT), Tenet (THC) and Universal Health (UHS).
06/06/17
LEER
06/06/17
UPGRADE
LEER
Outperform
LifePoint upgraded to Outperform from Market Perform at Leerink
06/07/17
LEER
06/07/17
UPGRADE
LEER
Outperform
Leerink upgrades hospitals HCA, LifePoint, Tenet to Outperform
Leerink analyst Ana Gupte last night upgraded hospitals HCA Holdings (HCA), LifePoint (LPNT) and Tenet healthcare (THC) to Outperform from Market Perform. She raised her price target for HCA to $100 from $90, for LifePoint to $74 from $73 and maintains a $27 price target for HCA. The targets offer upside of 21%, 20% and 62% respectively. Anthem's (ANTM) announced exit yesterday from the key swing state of Ohio's healthcare exchange could bring further attention to the need for stabilization funding through legislation, Gupte tells investors in a research note. She believes improving policy under the Trump Administration could drive upside to 2018 and 2019 consensus estimates. Further, the analyst thinks medium term downside risk from Republican's repeal and replace healthcare bill is likely better than feared as publicly traded hospitals are "heavily weighted to non-expansion states," which lessons the impact of Medicaid expansion funding cuts.
UIS Unisys
$12.43

0.08 (0.65%)

06/22/16
RHCO
06/22/16
INITIATION
Target $11
RHCO
Buy
Unisys initiated with a Buy at SunTrust
SunTrust analyst Frank Atkins initiated Unisys with a Buy and a $11 price target. The analyst said new management is refocusing the business to drive bookings and growth on the services side and stabilize declines on the Technology side. Atkins expects topline growth as well as improvement in margins should drive multiple expansion and notes the balance sheet has been restored, given it some room for investments.
01/10/17
LOOP
01/10/17
INITIATION
Target $15
LOOP
Hold
Unisys initiated with a Hold at Loop Capital
Loop Capital analyst Joseph Vafi initiated Unisys with a Hold and a $15 price target.
04/26/17
04/26/17
NO CHANGE

Unisys awarded digital services contract by Michigan Department of Technology
Unisys will provide a digital government solution to enable the Michigan Gaming Control Board to access information needed to license and regulate gaming activities in the state. Under the five-year, multimillion dollar contract, Unisys will create a modern, collaborative operating environment that digitizes the MGCB's records and documents.
11/15/16
RHCO
11/15/16
NO CHANGE
Target $15
RHCO
Buy
Unisys price target raised to $15 from $12 at SunTrust
SunTrust analyst Frank Atkins raised his price target for Unisys to $15 following the company's analyst day. The analyst keeps a Buy rating on the shares.
BLL Ball Corp.
$41.78

-0.01 (-0.02%)

05/05/17
VERT
05/05/17
DOWNGRADE
Target $83
VERT
Hold
Ball Corp. downgraded to Hold on limited upside at Vertical Research
Vertical Research analyst Chip Dillon downgraded Ball Corp to Hold from Buy citing limited upside to his new $83 price target, raised from $81.
03/02/17
GSCO
03/02/17
INITIATION
Target $80
GSCO
Neutral
Ball Corp. initiated with a Neutral at Goldman
Goldman analyst Brian Maguire initiated Ball Corp with a Neutral and an $80 price target saying it is a solid franchise but expectations are high. The analyst sees limited upside to consensus estimates that already surpass management's 2019 $2B EBITDA target.
05/25/17
JEFF
05/25/17
NO CHANGE
Target $47
JEFF
Buy
Ball Corp. risk/reward looks compelling, says Jefferies
Jefferies analyst Philip Ng views Ball Corp.'s risk/reward as compelling and notes the stock remains one of his top picks. The analyst believes Ball's industry backdrop is favorable and he sees multiple levers for the company to pull on cost synergies. Ng has a Buy rating on the shares with a $47 price target.
05/05/17
05/05/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Akamai (AKAM) downgraded to Neutral from Outperform at Baird with analyst William citing the lack of improving media trends, the lack of a near-term catalyst, and Street estimates that appear to him to be too high. Power lowered his price target to $55 from $60 on Akamai shares. 2. Celgene (CELG) downgraded to Hold from Buy at Argus with analyst David Toung citing valuation, Revlimid revenue concentration risk, and large discounts for Otezla. 3. Estee Lauder (EL) downgraded to Hold from Buy at Societe Generale. 4. Ball Corp. (BLL) downgraded to Hold on limited upside at Vertical Research with analyst Chip Dillon citing limited upside to his new $83 price target, which he raised from $81. 5. TreeHouse (THS) was downgraded to Market Perform from Outperform at Wells Fargo and to Neutral from Outperform at Wedbush. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
TTMI TTM Technologies
$18.03

0.16 (0.90%)

02/17/17
JPMS
02/17/17
DOWNGRADE
Target $18
JPMS
Neutral
TTM Technologies downgraded to Neutral from Overweight at JPMorgan
JPMorgan analyst Paul Coster downgraded TTM Technologies to Neutral citing valuation with the stock up 169% year-over-year. The analyst keeps an $18 price target for the shares. Coster believes end-market demand should be solid in FY17 and recommends investors stay in the shares.
04/04/17
JPMS
04/04/17
UPGRADE
Target $21
JPMS
Overweight
TTM Technologies upgraded to Overweight from Neutral at JPMorgan
JPMorgan analyst Paul Coster upgraded TTM Technologies to Overweight citing the recent pullback in the shares and potential earnings upside from the iPhone 8 cycle. The analyst views the current valuation as attractive and raised his price target for the shares to $21 from $18.
AMKR Amkor Technology
$10.68

0.01 (0.09%)

TODAY'S FREE FLY STORIES

AVA

Avista

$51.40

0.1 (0.19%)

18:47
09/22/17
09/22
18:47
09/22/17
18:47
Hot Stocks
Avista receives commission decision in Oregon natural gas rate case »

Avista's natural gas…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Nov

BMWYY

BMW

$34.00

0.083 (0.24%)

18:40
09/22/17
09/22
18:40
09/22/17
18:40
Periodicals
BMW to build new 8 series in Dingolfing from 2018, Reuters reports »

BMW intends to build its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CSCO

Cisco

$33.37

0.67 (2.05%)

18:20
09/22/17
09/22
18:20
09/22/17
18:20
Hot Stocks
Cisco completes acquisition of Springpath »

Cisco announced that it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Sep

  • 22

    Sep

  • 25

    Sep

  • 26

    Sep

  • 28

    Sep

  • 29

    Sep

  • 05

    Oct

  • 06

    Oct

  • 18

    Oct

  • 19

    Oct

  • 22

    Oct

  • 15

    Nov

  • 07

    Dec

  • 11

    Dec

BMY

Bristol-Myers

$63.36

0.03 (0.05%)

18:12
09/22/17
09/22
18:12
09/22/17
18:12
Hot Stocks
Bristol-Myers announces FDA approval of Opdivo »

Bristol-Myers announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Sep

  • 25

    Sep

  • 26

    Sep

  • 27

    Sep

  • 18

    Oct

  • 26

    Oct

  • 08

    Nov

  • 09

    Nov

  • 05

    Mar

INSE

Inspired Entertainment

$13.60

0.3 (2.26%)

17:38
09/22/17
09/22
17:38
09/22/17
17:38
Hot Stocks
Inspired Entertainment COO Wilson leaving by reason of redundancy »

On September 21, Inspired…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Sep

MNOV

MediciNova

$6.18

0.3 (5.10%)

17:30
09/22/17
09/22
17:30
09/22/17
17:30
Syndicate
Breaking Syndicate news story on MediciNova »

MediciNova files $200M…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

ISRG

Intuitive Surgical

$1,031.52

1.31 (0.13%)

17:25
09/22/17
09/22
17:25
09/22/17
17:25
Conference/Events
Intuitive Surgical to host special shareholder meeting »

Special Shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Sep

GD

General Dynamics

$205.41

-0.31 (-0.15%)

17:21
09/22/17
09/22
17:21
09/22/17
17:21
Hot Stocks
General Dynamics Electric Boat awarded $341.2M government contract modification »

General Dynamics Electric…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CHRS

Coherus Biosciences

$12.85

0.3 (2.39%)

17:19
09/22/17
09/22
17:19
09/22/17
17:19
Syndicate
Breaking Syndicate news story on Coherus Biosciences »

Coherus Biosciences files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

FIBK

First Interstate

$36.90

0.3 (0.82%)

17:18
09/22/17
09/22
17:18
09/22/17
17:18
Syndicate
First Interstate files to sell $250M of Class A common stock »

The shelf registration…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NRCIA

National Research, also tag NRCIB

$37.45

0.55 (1.49%)

, NRCIB

National Research, also tag NRCIA

$54.30

0.31 (0.57%)

17:08
09/22/17
09/22
17:08
09/22/17
17:08
Hot Stocks
National Research launches metric to measure healthcare consumer loyalty »

NRC Health launched the…

NRCIA

National Research, also tag NRCIB

$37.45

0.55 (1.49%)

NRCIB

National Research, also tag NRCIA

$54.30

0.31 (0.57%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CC

Chemours

$51.79

-0.16 (-0.31%)

, HON

Honeywell

$141.75

0.89 (0.63%)

16:58
09/22/17
09/22
16:58
09/22/17
16:58
Hot Stocks
Chemours files appeal concerning SNAP 20 rule to regulate HFCs »

The Chemours Company (CC)…

CC

Chemours

$51.79

-0.16 (-0.31%)

HON

Honeywell

$141.75

0.89 (0.63%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AGN

Allergan

$204.65

1.99 (0.98%)

16:57
09/22/17
09/22
16:57
09/22/17
16:57
Hot Stocks
Allergan receives refusal to file letter from FDA for Vraylar »

Allergan announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

HON

Honeywell

$141.75

0.89 (0.63%)

, CC

Chemours

$51.79

-0.16 (-0.31%)

16:51
09/22/17
09/22
16:51
09/22/17
16:51
Hot Stocks
Honeywell, Chemours seek rehearing of D.C Court decision regarding SNAP program »

Honeywell (HON) and…

HON

Honeywell

$141.75

0.89 (0.63%)

CC

Chemours

$51.79

-0.16 (-0.31%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JOE

Saint Joe Co.

$18.60

0.45 (2.48%)

16:46
09/22/17
09/22
16:46
09/22/17
16:46
Hot Stocks
Breaking Hot Stocks news story on Saint Joe Co. »

Fairholme raises stake in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

16:40
09/22/17
09/22
16:40
09/22/17
16:40
General news
Moody's downgrades UK's rating to Aa2, changes outlook to stable »

Moody's Investors…

A

Agilent

$65.78

-0.14 (-0.21%)

, MRK

Merck

$65.13

-0.47 (-0.72%)

16:36
09/22/17
09/22
16:36
09/22/17
16:36
Hot Stocks
Agilent receives expanded FDA approval for the use of Dako PD-L1 IHC 22C3 »

Agilent Technologies…

A

Agilent

$65.78

-0.14 (-0.21%)

MRK

Merck

$65.13

-0.47 (-0.72%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Sep

  • 26

    Sep

  • 08

    Nov

  • 30

    Nov

TYHT

Shineco

$3.23

-0.45 (-12.23%)

16:35
09/22/17
09/22
16:35
09/22/17
16:35
Hot Stocks
Shineco enters into strategic cooperation to establish Apocynum Industrial Park »

Shineco announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ARCI

Appliance Recycling

$1.16

0.03 (2.65%)

16:34
09/22/17
09/22
16:34
09/22/17
16:34
Hot Stocks
Appliance Recycling gets written notice of default »

On September 20,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RNVA

Rennova Health

$0.22

0.0086 (4.07%)

16:31
09/22/17
09/22
16:31
09/22/17
16:31
Hot Stocks
Rennova Health announces 1 for 15 reverse stock split »

Rennova Health announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ARCI

Appliance Recycling

$1.16

0.03 (2.65%)

16:31
09/22/17
09/22
16:31
09/22/17
16:31
Hot Stocks
Breaking Hot Stocks news story on Appliance Recycling »

Appliance Recycling gets…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

16:30
09/22/17
09/22
16:30
09/22/17
16:30
Options
Preliminary option volume of 13.9M today »

Preliminary option volume…

EKSO

Ekso Bionics

$1.28

0.14 (12.28%)

16:23
09/22/17
09/22
16:23
09/22/17
16:23
Hot Stocks
Ekso Bionics awarded government contract »

The Department of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UNH

UnitedHealth

$193.03

-2.18 (-1.12%)

, AET

Aetna

$153.57

0.18 (0.12%)

16:22
09/22/17
09/22
16:22
09/22/17
16:22
General news
On The Fly: Top stock stories for Friday »

The major averages…

UNH

UnitedHealth

$193.03

-2.18 (-1.12%)

AET

Aetna

$153.57

0.18 (0.12%)

ANTM

Anthem

$182.86

-0.64 (-0.35%)

CI

Cigna

$182.74

0.61 (0.33%)

AAPL

Apple

$151.89

-1.5 (-0.98%)

FSLR

First Solar

$51.41

2.65 (5.43%)

FINL

Finish Line

$9.73

0.51 (5.53%)

ASND

Ascendis Pharma

$34.24

6.5 (23.43%)

VSAR

Versartis

$2.68

-18.925 (-87.62%)

ICPT

Intercept

$61.59

-12.11 (-16.43%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Sep

  • 22

    Oct

DLR

Digital Realty

$114.51

-1.72 (-1.48%)

16:19
09/22/17
09/22
16:19
09/22/17
16:19
Syndicate
Breaking Syndicate news story on Digital Realty »

Digital Realty files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.